THE PROJECT
Xemperia is a spin-off project of the University of Fribourg. It aims to introduce a new generation of diagnostic solutions in medicine for the benefit of patients and the society. It is built on more than 25 years of experience in experimental and translational breast cancer research and biomarker discovery. The project is directed by and conducted by the team at University of Fribourg in collaboration with clinical partners.
ROADMAP
THE TEAM
Curzio Rüegg
CEO / CSO
Professor – Chair of Pathology and Translational oncology (UNIFR, Fribourg).
MD, trained in internal medicine, immunology, cell and molecular biology (Basel, Zürich, San Francisco).
Member of over 25 national and international boards and committees. Member of the Swiss Academy of Medical Sciences. Over 30 Mio CHF competitive funding obtained; > 170 publications; 9 patents.
Tuto Rossi
Legal Affairs
Law and notary firm in Bellinzona
Sarah Cattin
CTO
Senior Scientist
MSc in Medical Biology, specialization in immunology and cancer, UNIL (Lausanne).
Translational research and Head of cell analytics facility, UNIFR (Fribourg).
Frédéric Fer
Biostatistician
MSc in bioinformatics & biostatistics, University of Nantes (Nantes).
Senior Biostatistician (La Selpetrière, Paris).
Ivana Domljanovic
Scientist
PhD in Medical science – Diagnostics and DNA nanotechnology, UNIFR (Fribourg).
Research Associate – Cancer Research , UNIFR (Fribourg)
> Find publications about our research: https://www.unifr.ch/med/de/research/group/ruegg/publications.html
OUR PARTNERS
The project is conducted in collaboration with clinical partners for the design and recruitments of patients:
THE GENOA BIOBANK
A dedicated biobank to collect and store all samples was established et UNIFR and certified by the Swiss Biobanking Platform.
SUPPORTED BY
PATENTS
Multiple patents have been filed to protect our inventions.